» Articles » PMID: 37111265

Trends in the Use of Driving-Impairing Medicines According to the DRUID Category: A Population-Based Registry Study with Reference to Driving in a Region of Spain Between 2015 and 2019

Overview
Publisher MDPI
Specialty Chemistry
Date 2023 Apr 28
PMID 37111265
Authors
Affiliations
Soon will be listed here.
Abstract

The European DRUID (Drive Under the Influence of drugs, alcohol, and medicines) program classifies medications into three categories according to their effect on one's fitness to drive. The trend in the use of driving-impairing medicines (DIMs) in a region of Spain between 2015 and 2019 was analyzed through a population-based registry study. Pharmacy dispensing records for DIMs are provided. The use of DIMs on drivers was weighted according to the national driver's license census. The analysis was performed considering the population distribution by age and sex, treatment length, and the three DRUID categories. DIMs were used by 36.46% of the population and 27.91% of drivers, mainly chronically, with considerable daily use (8.04% and 5.34%, respectively). Use was more common in females than in males (42.28% vs. 30.44%) and increased with age. Among drivers, consumption decreases after 60 years of age for females and after 75 years of age for males. There was a 34% increase in the use of DIMs between 2015 and 2019, with a focus on daily use (>60%). The general population took 2.27 ± 1.76 DIMs, fundamentally category II (moderate influence on fitness to drive) (20.3%) and category III (severe influence on fitness to drive) (19.08%). The use of DIMs by the general population and drivers is significant and has increased in recent years. The integration of the DRUID classification into electronic prescription tools would assist physicians and pharmacists in providing adequate information to the patient about the effects of prescribed medications on their fitness to drive.

Citing Articles

Medication Changes Among Older Drivers Involved in Motor Vehicle Crashes.

Zullo A, Riester M, DAmico A, Reddy Bhuma M, Khan M, Curry A JAMA Netw Open. 2024; 7(10):e2438338.

PMID: 39382896 PMC: 11581636. DOI: 10.1001/jamanetworkopen.2024.38338.


Changes in the burden of medications that may impair driving among older adults before and after a motor vehicle crash.

Riester M, DAmico A, Khan M, Joyce N, Pfeiffer M, Margolis S J Am Geriatr Soc. 2023; 72(2):444-455.

PMID: 37905738 PMC: 10922040. DOI: 10.1111/jgs.18643.

References
1.
Ravera S, Monteiro S, de Gier J, Van der Linden T, Gomez-Talegon T, Alvarez F . A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012; 74(6):920-31. PMC: 3522805. DOI: 10.1111/j.1365-2125.2012.04279.x. View

2.
Benchimol E, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I . The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015; 12(10):e1001885. PMC: 4595218. DOI: 10.1371/journal.pmed.1001885. View

3.
Gutierrez-Abejon E, Herrera-Gomez F, Criado-Espegel P, Alvarez F . Use of driving-impairing medicines by a Spanish population: a population-based registry study. BMJ Open. 2017; 7(11):e017618. PMC: 5719315. DOI: 10.1136/bmjopen-2017-017618. View

4.
Simo Minana J . [Use of prescription drugs in Spain and Europe]. Aten Primaria. 2011; 44(6):335-47. PMC: 7025249. DOI: 10.1016/j.aprim.2011.06.009. View

5.
Emich B, van Dijk L, Monteiro S, de Gier J . A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines. Int J Clin Pharm. 2014; 36(6):1152-9. DOI: 10.1007/s11096-014-0010-2. View